Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 2
1981 2
1983 2
1984 2
1988 1
1994 1
1996 1
1998 2
2000 7
2001 4
2002 1
2003 1
2004 3
2005 1
2006 1
2009 3
2010 4
2011 6
2012 7
2013 12
2014 14
2015 12
2016 21
2017 16
2018 17
2019 33
2020 29
Text availability
Article attribute
Article type
Publication date

Search Results

185 results
Results by year
Filters applied: . Clear all The following term was not found in PubMed: Sugihartati
Page 1
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.
Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, Davis JL, Hughes MS, Heller T, ElGindi M, Uppala A, Korangy F, Kleiner DE, Figg WD, Venzon D, Steinberg SM, Venkatesan AM, Krishnasamy V, Abi-Jaoudeh N, Levy E, Wood BJ, Greten TF. Duffy AG, et al. J Hepatol. 2017 Mar;66(3):545-551. doi: 10.1016/j.jhep.2016.10.029. Epub 2016 Nov 2. J Hepatol. 2017. PMID: 27816492 Free PMC article. Clinical Trial.
Aging, immune senescence, and immunotherapy: A comprehensive review.
Elias R, Hartshorn K, Rahma O, Lin N, Snyder-Cappione JE. Elias R, et al. Semin Oncol. 2018 Aug;45(4):187-200. doi: 10.1053/j.seminoncol.2018.08.006. Epub 2018 Oct 24. Semin Oncol. 2018. PMID: 30539714 Review.
The Intersection between Tumor Angiogenesis and Immune Suppression.
Rahma OE, Hodi FS. Rahma OE, et al. Clin Cancer Res. 2019 Sep 15;25(18):5449-5457. doi: 10.1158/1078-0432.CCR-18-1543. Epub 2019 Apr 3. Clin Cancer Res. 2019. PMID: 30944124 Review.
Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis.
Elias R, Giobbie-Hurder A, McCleary NJ, Ott P, Hodi FS, Rahma O. Elias R, et al. J Immunother Cancer. 2018 Apr 4;6(1):26. doi: 10.1186/s40425-018-0336-8. J Immunother Cancer. 2018. PMID: 29618381 Free PMC article.
Incidence and contributing factors of glucose intolerance in Saudi postpartum women: Sub-group analysis from RAHMA study.
Wahabi H, Fayed A, Tunkar SMS, Bakhsh H, Al-Hazmi AM, Esmaeil S, Siddiqui AR. Wahabi H, et al. PLoS One. 2019 Jan 7;14(1):e0210024. doi: 10.1371/journal.pone.0210024. eCollection 2019. PLoS One. 2019. PMID: 30615670 Free PMC article.
OBJECTIVES: The objectives of this study were to determine incidence and risk factors of glucose intolerance one year after delivery in a sub-cohort of Riyadh Mother and Baby Cohort Study (RAHMA) study. METHODS: This is a follow-up study of a sub-cohort from RAHMA s …
OBJECTIVES: The objectives of this study were to determine incidence and risk factors of glucose intolerance one year after delivery in a su …
Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma.
Duffy AG, Ma C, Ulahannan SV, Rahma OE, Makarova-Rusher O, Cao L, Yu Y, Kleiner DE, Trepel J, Lee MJ, Tomita Y, Steinberg SM, Heller T, Turkbey B, Choyke PL, Peer CJ, Figg WD, Wood BJ, Greten TF. Duffy AG, et al. Clin Cancer Res. 2017 Aug 15;23(16):4633-4641. doi: 10.1158/1078-0432.CCR-16-3171. Epub 2017 May 2. Clin Cancer Res. 2017. PMID: 28465443 Free PMC article. Clinical Trial.
Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
Gentzler R, Hall R, Kunk PR, Gaughan E, Dillon P, Slingluff CL Jr, Rahma OE. Gentzler R, et al. Immunotherapy. 2016 May;8(5):583-600. doi: 10.2217/imt-2015-0029. Immunotherapy. 2016. PMID: 27140411 Review.
185 results
Jump to page
Feedback